Cancer Therapeutics Market Will Grow 7.8% to a Record $ 176 Bn by 2026

​Acumen Research and Consulting estimate that this new round of Cancer Therapeutics Market will top $176 billion by 2026, representing an average annual growth rate of 7.8 percent from the forecast period 2019 to 2026.

In 2018, North America dominated the regional market with maximum share. The well-established healthcare infrastructure and early adoption of new technologies in the region is favoring market growth. The high prevalence of cancer in the region due to the rapidly changing lifestyle is contributing to the market growth. In addition, according to National Cancer Institute (NCI), 15.5 million cancer survivors were estimated in the United States in the year 2016. Additionally, according to the institute, US-based cancer survivors are anticipated to increase to 20.3 million during the forecast period of 2026.

On the basis of application, breast cancer accounted for the largest market share in the year 2018 and the cancer type is also expected to maintain its dominance over the forecast period owing to its high prevalence. For instance, scientists at the Institute of Cancer Research (ICR) in London announced that they have found a way to prevent the escape of triple-negative breast cancer cells, and the new way can disrupt the key process in the evolution of cancer. The team has used a drug from Boston Pharmaceuticals called BOS172722 for the rapid division of cancer cells. Apart from these, breast cancer is also diagnosed as the most common cancer in the US region, which is also supporting the growth of the segment.

Free Download Sample Report Pages for Better understanding@ https://www.acumenresearchandconsulting.com/request-sample/1626

By treatment type, targeted therapy dominated the market with the largest share and the segment is also expected to maintain its dominance over the forecast period owing to its advantage over its substitutes. The advantage associated with the targeted therapy includes less harm to normal cells and fewer side effects among others. The targeted therapy is used as maintenance treatment for advanced cancer to prevent the comeback cancer is also a factor supporting the growth of the segment.

Some of the leading competitors are AbbVie Inc., Astellas Pharma Inc., Bristol Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co., Inc., Novartis AG, and Pfizer Inc. among others. The key players of the cancer therapeutics market are involved in research & development activities for providing more advanced and efficient solutions to the patients for early recovery.

Related Reports:

  • Dialysis Market - The global market is expected to grow at a CAGR of around 5.7% from 2019 to 2026 and expected to reach the market value of around US$ 124.2 Bn by 2026.
  • Artificial Intelligence for Drug Discovery Market- The global market size is expected to reach around US$ 8,149 Mn by 2026 and is expected to register a CAGR of above 42% over the forecast period 2019 to 2026.
  • Healthcare Staffing Market - The global market value is expected to reach around US$ 45.2 Bn by 2026 and growing at a CAGR of around 5.2% over the forecast period 2019 to 2026.

Some of the key observations regarding Cancer Therapeutics industry include:

  • Kymera Therapeutics Inc., a biotechnology company announced to present preclinical data demonstrating the potency and antitumor activity of a selective stat3 degrader at the AACR-NCI-EORTC international conference in 2019, focused on molecular targets and cancer therapeutics.
  • The Texas Medical Center (TMC) Innovation Institute campus comprises several different enterprises from labs to co-working spaces to accelerator programs. The TMC innovation is starting a new program for early-stage startups, which are focused on developing novel cancer therapeutics.
  • Mirati Therapeutics, Inc. a clinical-stage targeted oncology company, announced to present a Pre-Clinical And Initial Clinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in 2019 at Hynes Convention Center, Boston. The data is focused on MRTX849, a novel and optimized KRAS G12C inhibitor.
  • Virginia Tech has announced a cancer research initiative with the development of a university-wide cancer research strategy. The strategy is intended for creating and expanding synergies among more than 30 existing research teams. The initiative is focused to find a new way to prevent, quickly diagnose, and treat cancers.
  • Verseau Therapeutics, Inc. launched with US$50 Mn in financing from 3SBio, Alexandria Venture Investments, 20/20 HealthCare Partners, Highlight Capital, InHarv Partners Ltd., The Mark Foundation for Cancer Research and Yonghua Capital. The launch is intended to develop in-Class Macrophage-Targeted Immunotherapies. Former Executive Vice President of Celgene and a champion of innovation honored with Ph.D. named George Golumbeski, appointed as the chairman of the Verseau Board of Directors.
  • Immunomic Therapeutics, Inc. announced a presentation in 2019 at the Precision Lung Cancer World R&D Summit, Boston. The talk is likely to be initiated by the Business Development Advisor of Immunomic, with the title "Current & Future Application of the UNITE Platform in Cancer Immunotherapy."

View Detail Information with Complete TOC@ https://www.acumenresearchandconsulting.com/cancer-therapeutics-market

Cancer Therapeutics Market (By Application: Blood Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head and Neck Cancer, Glioblastoma, Malignant Meningioma, Mesothelioma, Melanoma, Others; By Treatment Type: Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy, Others) – Global Industry Analysis, Market Size, Opportunities And Forecast, 2019 - 2026

TABLE OF CONTENT

CHAPTER 1. INDUSTRY OVERVIEW
1.1. Definition and Scope
1.1.1. Definition of Pure Cashmere
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Cancer Therapeutics Market By Application
1.2.2.1. Global Cancer Therapeutics Market Revenue and Growth Rate Comparison By Application (2015-2026)
1.2.2.2. Global Cancer Therapeutics Market Revenue Share By Application in 2018
1.2.2.3. Blood Cancer
1.2.2.4. Colorectal Cancer
1.2.2.5. Prostate Cancer
1.2.2.6. Breast Cancer
1.2.2.7. Cervical Cancer
1.2.2.8. Head and Neck Cancer
1.2.2.9. Glioblastoma
1.2.2.10. Malignant Meningioma
1.2.2.11. Mesothelioma
1.2.2.12. Melanoma
1.2.2.13. Others
1.2.3. Cancer Therapeutics Market By Treatment Type
1.2.3.1. Global Cancer Therapeutics Market Revenue and Growth Rate Comparison By Treatment Type (2015-2026)
1.2.3.2. Global Cancer Therapeutics Market Revenue Share By Treatment Type in 2018
1.2.3.3. Chemotherapy
1.2.3.4. Targeted Therapy
1.2.3.5. Immunotherapy
1.2.3.6. Hormonal Therapy
1.2.3.7. Others
1.2.4. Cancer Therapeutics Market By Geography
1.2.4.1. Global Cancer Therapeutics Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.4.2. North America Cancer Therapeutics Market Revenue and Growth Rate (2015-2026)
1.2.4.3. Europe Cancer Therapeutics Market Revenue and Growth Rate (2015-2026)
1.2.4.4. Asia-Pacific Cancer Therapeutics Market Revenue and Growth Rate (2015-2026)
1.2.4.5. Latin America Cancer Therapeutics Market Revenue and Growth Rate (2015-2026)
1.2.4.6. Middle East and Africa (MEA) Cancer Therapeutics Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS
2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2018
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS
3.1. Capacity and Commercial Production Date of Global Pure Cashmere Major Manufacturers in 2018
3.2. Manufacturing Plants Distribution of Global Pure Cashmere Major Manufacturers in 2018
3.3. R&D Status and Technology Source of Global Pure Cashmere Major Manufacturers in 2018
3.4. Raw Materials Sources Analysis of Global Pure Cashmere Major Manufacturers in 2018

CHAPTER 4. CANCER THERAPEUTICS MARKET BY APPLICATION
4.1. Global Pure Cashmere Revenue By Application
4.2. Blood Cancer
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Lung Cancer
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Colorectal Cancer
4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.5. Prostate Cancer
4.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.6. Breast Cancer
4.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.7. Cervical Cancer
4.7.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.7.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.8. Head and Neck Cancer
4.8.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.8.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.9. Glioblastoma
4.9.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.9.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.10. Malignant Meningioma
4.10.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.10.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.11. Mesothelioma
4.11.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.11.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.12. Melanoma
4.12.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.12.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.13. Others
4.13.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.13.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 5. CANCER THERAPEUTICS MARKET BY TREATMENT TYPE
5.1. Global Pure Cashmere Revenue By Treatment Type
5.2. Chemotherapy
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Targeted Therapy
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. Immunotherapy
5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.5. Hormonal Therapy
5.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.6. Others
5.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 6. NORTH AMERICA CANCER THERAPEUTICS MARKET BY COUNTRY
6.1. North America Cancer Therapeutics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2. North America Cancer Therapeutics Market Revenue Share Comparison, 2015 & 2026 (%)
6.3. U.S.
6.3.1. U.S. Cancer Therapeutics Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
6.4. Canada
6.4.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
6.4.2. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)

CHAPTER 7. EUROPE CANCER THERAPEUTICS MARKET BY COUNTRY
7.1. Europe Cancer Therapeutics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2. Europe Cancer Therapeutics Market Revenue Share Comparison, 2015 & 2026 (%)
7.3. UK
7.3.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
7.4. Germany
7.4.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
7.5. France
7.5.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
7.5.2. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
7.6. Spain
7.6.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
7.6.2. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
7.7. Rest of Europe
7.7.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
7.7.2. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)

CHAPTER 8. ASIA-PACIFIC CANCER THERAPEUTICS MARKET BY COUNTRY
8.1. Asia-Pacific Cancer Therapeutics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. Asia-Pacific Cancer Therapeutics Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. China
8.3.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
8.4. Japan
8.4.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
8.5. India
8.5.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.5.2. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
8.6. Australia
8.6.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.6.2. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
8.7. South Korea
8.7.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.7.2. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
8.8. Rest of Asia-Pacific
8.8.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.8.2. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)

CHAPTER 9. LATIN AMERICA CANCER THERAPEUTICS MARKET BY COUNTRY
9.1. Latin America Cancer Therapeutics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Latin America Cancer Therapeutics Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. Brazil
9.3.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
9.4. Mexico
9.4.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
9.5. Rest of Latin America
9.5.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)

CHAPTER 10. MIDDLE EAST & AFRICA CANCER THERAPEUTICS MARKET BY COUNTRY
10.1. Middle East & Africa Cancer Therapeutics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Middle East & Africa Cancer Therapeutics Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. GCC
10.3.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
10.4. South Africa
10.4.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)
10.5. Rest of Middle East & Africa
10.5.1. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By Treatment Type, 2015 - 2026 ($Million)

CHAPTER 11. COMPANY PROFILE
11.1. AbbVie Inc.
11.1.1. Company Snapshot
11.1.2. Overview
11.1.3. Financial Overview
11.1.4. Product Portfolio
11.1.5. Key Developments
11.1.6. Strategies
11.2. Astellas Pharma Inc.
11.2.1. Company Snapshot
11.2.2. Overview
11.2.3. Financial Overview
11.2.4. Product Portfolio
11.2.5. Key Developments
11.2.6. Strategies
11.3. Bristol Myers Squibb Company
11.3.1. Company Snapshot
11.3.2. Overview
11.3.3. Financial Overview
11.3.4. Product Portfolio
11.3.5. Key Developments
11.3.6. Strategies
11.4. Celgene Corporation
11.4.1. Company Snapshot
11.4.2. Overview
11.4.3. Financial Overview
11.4.4. Product Portfolio
11.4.5. Key Developments
11.4.6. Strategies
11.5. Eli Lilly and Company
11.5.1. Company Snapshot
11.5.2. Overview
11.5.3. Financial Overview
11.5.4. Product Portfolio
11.5.5. Key Developments
11.5.6. Strategies
11.6. F. Hoffmann-La Roche Ltd.
11.6.1. Company Snapshot
11.6.2. Overview
11.6.3. Financial Overview
11.6.4. Product Portfolio
11.6.5. Key Developments
11.6.6. Strategies
11.7. Johnson & Johnson
11.7.1. Company Snapshot
11.7.2. Overview
11.7.3. Financial Overview
11.7.4. Product Portfolio
11.7.5. Key Developments
11.7.6. Strategies
11.8. Merck & Co., Inc.
11.8.1. Company Snapshot
11.8.2. Overview
11.8.3. Financial Overview
11.8.4. Product Portfolio
11.8.5. Key Developments
11.8.6. Strategies
11.9. Novartis AG
11.9.1. Company Snapshot
11.9.2. Overview
11.9.3. Financial Overview
11.9.4. Product Portfolio
11.9.5. Key Developments
11.9.6. Strategies
11.10. Pfizer Inc.
11.10.1. Company Snapshot
11.10.2. Overview
11.10.3. Financial Overview
11.10.4. Product Portfolio
11.10.5. Key Developments
11.10.6. Strategies
11.11. Others
11.11.1. Company Snapshot
11.11.2. Overview
11.11.3. Financial Overview
11.11.4. Product Portfolio
11.11.5. Key Developments
11.11.6. Strategies

CHAPTER 12. RESEARCH APPROACH
12.1. Research Methodology
12.1.1. Initial Data Search
12.1.2. Secondary Research
12.1.3. Primary Research
12.2. Assumptions and Scope

The report is readily available and can be dispatched immediately after payment confirmation.

Buy this premium research report – https://www.acumenresearchandconsulting.com/buy-now/0/1626

If you would like to place an order or have any questions, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 4157 OR +1 408 900 9135

About Acumen Research and Consulting:

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.

Contact Us:

Phone: +14079154157 | +14089009135

Website: https://www.acumenresearchandconsulting.com

Follow Us: LinkedIN | Twitter